Xeris Biopharma Holdings, Inc. (XERS)

Xeris Biopharma Holdings Statistics

Total Valuation

XERS has a market cap or net worth of $663.48 million. The enterprise value is $863.31 million.

Market Cap	663.48M
Enterprise Value	863.31M

Important Dates

The next estimated earnings date is Thursday, May 8, 2025, before market open.

Earnings Date	May 8, 2025
Ex-Dividend Date	n/a

Share Statistics

XERS has 153.94 million shares outstanding. The number of shares has increased by 6.61% in one year.

Current Share Class	153.94M
Shares Outstanding	153.94M
Shares Change (YoY)	+6.61%
Shares Change (QoQ)	+0.07%
Owned by Insiders (%)	4.73%
Owned by Institutions (%)	42.85%
Float	146.66M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.12
Forward PS	2.61
PB Ratio	-22.40
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	4.25
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.67

Current Ratio	1.67
Quick Ratio	1.12
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-0.90

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-5.33%
Return on Invested Capital (ROIC)	-7.42%
Return on Capital Employed (ROCE)	-12.37%
Revenue Per Employee	$515,406
Profits Per Employee	-$139,178
Employee Count	394
Asset Turnover	0.63
Inventory Turnover	0.85

Taxes

Income Tax	-2.27M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +144.89% in the last 52 weeks. The beta is 0.89, so XERS's price volatility has been lower than the market average.

Beta (5Y)	0.89
52-Week Price Change	+144.89%
50-Day Moving Average	4.47
200-Day Moving Average	3.39
Relative Strength Index (RSI)	46.86
Average Volume (20 Days)	3,095,413

Short Selling Information

The latest short interest is 17.04 million, so 11.07% of the outstanding shares have been sold short.

Short Interest	17.04M
Short Previous Month	11.21M
Short % of Shares Out	11.07%
Short % of Float	11.62%
Short Ratio (days to cover)	4.02

Income Statement

In the last 12 months, XERS had revenue of $203.07 million and -$54.84 million in losses. Loss per share was -$0.37.

Revenue	203.07M
Gross Profit	166.24M
Operating Income	-27.55M
Pretax Income	-59.08M
Net Income	-54.84M
EBITDA	-15.48M
EBIT	-27.55M
Loss Per Share	-$0.37

Balance Sheet

The company has $71.62 million in cash and $271.45 million in debt, giving a net cash position of -$199.83 million or -$1.30 per share.

Cash & Cash Equivalents	71.62M
Total Debt	271.45M
Net Cash	-199.83M
Net Cash Per Share	-$1.30
Equity (Book Value)	-29.62M
Book Value Per Share	-0.20
Working Capital	67.22M

Cash Flow

In the last 12 months, operating cash flow was -$36.98 million and capital expenditures -$868,000, giving a free cash flow of -$37.85 million.

Operating Cash Flow	-36.98M
Capital Expenditures	-868,000
Free Cash Flow	-37.85M
FCF Per Share	-$0.25

Margins

Gross margin is 81.86%, with operating and profit margins of -13.56% and -27.00%.

Gross Margin	81.86%
Operating Margin	-13.56%
Pretax Margin	-28.12%
Profit Margin	-27.00%
EBITDA Margin	-7.62%
EBIT Margin	-13.56%
FCF Margin	n/a

Dividends & Yields

XERS does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-6.61%
Shareholder Yield	-6.61%
Earnings Yield	-8.26%
FCF Yield	-5.70%

Analyst Forecast

The average price target for XERS is $6.10, which is 41.53% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$6.10
Price Target Difference	41.53%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	19.68%
EPS Growth Forecast (5Y)	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

XERS has an Altman Z-Score of -1.67 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.67
Piotroski F-Score	3